Pre-Clinical CROs 

2023/24 Edition

Potentially disruptive, independent providers of pre-clinical pharma CRO services, based in North America and Europe.

Welcome to our Watchlist

We are delighted to present the 2023/24 edition of our Pre-Clinical Contract Research Organisation (CRO) Watchlist. This edition contains 363 independent businesses across Europe and North America, and highlights and applauds 15 of the most innovative operators in the space. 

To create this Watchlist, we screened our proprietary chemicals and life sciences database, prepared profiles, and consulted with our expert panel. We then contacted each of the companies identified to check our data, interview the executive leaders, and gain insight into their strategic ambitions.

"This Watchlist includes 363 independent players in the pre-clinical CRO space, each of which has the potential to disrupt the established market in the next few years. These are the ones to watch."

Matt Dixon

Managing Partner, CCD Partners

Cohort Analysis

Our Watchlist features analysis on a wider set of companies operating in the Pre-Clinical CRO space. Here are three takeaways from the report:

1. Our Watchlist focusses on North America and European companies

3. Privately owned companies form the core of our Watchlists

2. We analysed companies with a broad range of pre-clinical services